- Clinical artificial intelligence technology company Sensyne Health posted a maiden interim loss as a public company after ramping up R&D other investment spending.

Losses from continuing operations in the six months through October amounted to £10.3m, compared to losses of £3.4m on-year.

The loss was also driven by higher spending on marketing and other general and administrative expenses, including hiring new staff.

Continued recruitment to progress commercial activity was expected to lead to an increased operating loss for the remainder of the year, Sensyne Health said.

Cash and cash equivalents at 31 October were £57.7m.

Separately, the company announced three separate deals, including an agreement with Jefferson Health for the evaluation of its digital therapeutic product, and generation of patient data within a US hospital system.

The second involved two NHS Trust strategic research agreements -- with George Eliot NHS Trust and Wye Valley NHS Trust -- for which each would issued with £2.5m in ordinary shares in the company at £1.75 per share.

The third was a research agreement with the Big Data Institute at the University of Oxford using Sensyne's anonymised patient data, focused in the field of chronic disease, including chronic kidney disease and cardiovascular disease.

At 1:43pm: [LON:SENS] Sensyne Health Plc Ord 10p share price was +11p at 167p

Story provided by